ReviewFrontiers in immunology2022
Interplay between Solid Tumors and Tumor Microenvironment.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity.Cancer immunology research · 2026Article
- A novel "early warning" system for biochemical recurrence in prostate cancer: development and validation of the SII-HALP combined score.BMC cancer · 2026Article
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Tumor-stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer.FEBS open bio · 2026Article
- Macrophage-derived extracellular vesicles in the remodeling of the prostate cancer immune microenvironment and therapeutic resistance.Journal of translational medicine · 2026Review
- Growth differentiation factor 11 reprograms M2-like macrophages: Targeting immunometabolism for cancer therapy.World journal of gastroenterology · 2026Article
- Tumor-specific antibody cocktail treatment suppresses colorectal tumor growth in mice.Cancer immunology, immunotherapy : CII · 2026Article
- Rational engineering of combinatorial bacterial therapies for cancer.Genome biology · 2026Review
- Convergent Roles of Growth Differentiation Factor-15 (GDF-15) in Mechanotransduction, Vascular Disorganization, and Immune Suppression in Melanoma.bioRxiv : the preprint server for biology · 2026Article
- Collision Tumors Involving Metastatic Carcinoma and Plasma Cell Myeloma: Report of Two Cases.Case reports in pathology · 2026Article
- Imaging the fate of CAR-T cellsFrontiers in immunology · 2026Review
- Integration of tumor microenvironment and metabolic signatures reveals TMPI-defined prognostic and immunotherapy-relevant phenotypes in breast cancer.Frontiers in pharmacology · 2026Article
- Review
- GPU-accelerated volumetric-mosaic optical-resolution photoacoustic microscopy and quantifying tumor vasculature growth.Photoacoustics · 2025Article
- Comprehensive Pan-Cancer Analysis of ZNF668 Reveals the Prognostic and Immunological Significance of ZNF668.Current issues in molecular biology · 2025Article
- Advanced Microfluidics for Single Cell-Based Cancer Research.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR-T Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Dynamic Hydrogels: Adaptive Biomaterials for Engineering Tumor Microenvironment and Cancer Treatment.International journal of molecular sciences · 2025Review
- Comprehensive analysis of FAM83B in pan-cancer and preliminary exploration in esophageal squamous cell carcinoma.Journal of molecular histology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few decades, basic studies aimed at curing patients with cancer have been constantly evolving. A myriad of mechanistic studies on physiological changes and related factors in tumor growth and metastasis have been reported. Recently, several studies have been considerate to how tumors adapt to unfavorable environments, such as glucose deprivation, oxidative stress, hypoxic conditions, and immune responses. Tumors attempt to adapt to unfavorable environments with genetic or non-genetic changes, the alteration of metabolic signals, or the reconfiguration of their environment through migration to other organs. One of the distinct features in solid tumors is heterogeneity because their environments vary due to the characteristics of colony growth. For this reason, researchers are paying attention to the communication between growing tumors and neighboring environments, including stromal cells, immune cells, fibroblasts, and secreted molecules, such as proteins and RNAs. During cancer survival and progression, tumor cells undergo phenotype and molecular changes collectively referred to as cellular plasticity, which result from microenvironment signals, genetics and epigenetic alterations thereby contributing to tumor heterogeneity and therapy response. In this review, we herein discuss the adaptation process of tumors to adverse environments
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.